PROCESS AND METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE

• Main Authors: PALLARES, DIEGO, BRACCO, LAURENT, JARRIGE-LE PRADO, ANNEARLOTTE, ROUET, FABIEN, BEURDELEY, PASCALE
• Format: Patent
• Language: English; French; German
• Published: 15.12.2010
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

In vitro or ex vivo process for detecting the presence of Alzheimer's disease, the severity/advancement of Alzheimer's disease, or the risk of developing Alzheimer's disease, comprises determining the presence of an alteration in one or more genes or RNA comprising a sequence comprising SEQ ID NOs: 1-5578, in a biological sample of mammal, preferably blood sample, where the SEQ ID NOs. 1-5578 are not defined. In vitro or ex vivo process for detecting the presence of Alzheimer's disease, the severity/advancement of Alzheimer's disease, or the risk of developing Alzheimer's disease in a mammal, comprises determining the presence of an alteration in one or more genes or RNA comprising a sequence comprising SEQ ID NOs: 1-5578, in a biological sample of mammal, preferably blood sample, where the presence of alteration is indicative of the presence of Alzheimer's disease, the presence of alteration is indicative of severity/advancement of Alzheimer's disease, or the presence of alteration is indicative of risk of developing Alzheimer's disease in the mammal, and the SEQ ID NOs. 1-5578 are not defined. Independent claims are included for: (1) a process for evaluating or monitoring the response to a treatment for Alzheimer's disease, comprising measuring the expression of one or more genes or RNA comprising SEQ ID NOs: 1-5578 during treatment, and comparing the measured expression with the expression measured at an earlier stage of treatment or therapy; (2) a process for identifying patients to respond effectively to a treatment of Alzheimer's disease, comprising a step of measuring the expression of one or more genes or RNA comprising sequence SEQ ID NOs: 1-5578 during treatment, and comparing the expression thus measured with that measured at an earlier stage of treatment; (3) a process for identifying patients to respond effectively to a treatment of Alzheimer's disease, comprising measuring of expression of one or more genes or RNA comprising sequence SEQ ID NOs: 1-5578 before treatment, where the presence of alteration in the expression of the genes or RNA is indicative of the success of the treatment; (4) a product comprising a support on which nucleic acids are immobilized, comprising a complementary and/or specific sequence of at least 2, 5, 10, 20, 30, 40, 50, 60 or more genes or RNA; and (5) a kit comprising a compartment or container comprising at least 2, 5, 10, 20, 30, 40, 50, 60 or more nucleic acids and/or different ligands of nucleic acids and ligands. ACTIVITY : Neuroprotective; Nootropic. MECHANISM OF ACTION : None given.